| 摘要 |
Use of a compound chosen from the group comprising the following: verapamil, cyclosporin A, trifluoroperazine, thioridazine, chlorpromazine, quinidine, chloroquine, perhexiline and nifedipine or a pharmaceutically acceptable salt of the aforementioned compound, for the manufacture of a medicament which is useful for implementing a method for reversing the resistance to multiple medicaments in relation to synthetic anticancer agents, in particular bisantrene in man or warm-blooded animals, by co-administration thereto of the aforementioned compound with the aforementioned synthetic anticancer agent.
|
